Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment

International Journal of Cancer

Volumn 121, Issue 11, 2007, Pages 2492-2500

  Gee, Michael S ^a   Upadhyay, Rabi ^a   Bergquist, Henry ^a   Weissleder, Ralph ^a   Josephson, Lee ^a   Mahmood, Umar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibody therapy; Apoptosis; Breast cancer; HER2 neu; Molecular imaging; Trastuzumab

Indexed keywords

ALEXA FLUOR 750; ANNEXIN; CYANINE DYE 5; CYANINE DYE 5.5; CYTOTOXIC AGENT; FLUORESCENT DYE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANNEXINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED; UP-REGULATION;

EID: 35648964095     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22995     Document Type: Article

References (35)

1. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11:7967-85.
2. Kimura F. Molecular target drug discovery. Intern Med 2007;46:87-9.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
4. Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol 2003;7:490-5.
5. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5.
6. Shah K, Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. Neuro Rx 2005;2:215-25.
7. Weissleder R. Molecular imaging in cancer. Science 2006;312:1168-71.
8. Mahmood U, Tung CH, Tang Y, Weissleder R. Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology 2002;224:446-51.
9. Jobsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 1977;198:1264-7.
10. Taroni P, Pifferi A, Torricelli A, Comelli D, Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. Photochem Photobiol Sci 2003;2:124-9.
11. Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini G, Cubeddu R. Characterization of female breast lesions from multi-wavelength time-resolved optical mammography. Phys Med Biol 2005;50:2489-502.
12. Zhu Q, Cronin EB, Currier AA, Vine HS, Huang M, Chen N, Xu C. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology 2005;237:57-66.
13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
14. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
15. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A, Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42.
16. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-6.
17. Huang Q, Shan S, Braun RD, Lanzen J, Anyrhambatla G, Kong G, Borelli M, Corry P, Dewhirst MW, Li CY. Noninvasive visualization of tumors in rodent dorsal skin window chambers. Nat Biotechnol 1999;17:1033-5.
18. Alencar H, Mahmood U, Kawano Y, Hirata T, Weissleder R. Novel multiwavelength microscopic scanner for mouse imaging. Neoplasia 2005;7:977-83.
19. Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996;56:1457-65.
20. Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin downregulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;11:2008-17.
21. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002;62:5703-10.
22. Hilger I, Leistner Y, Berndt A, Fritsche C, Haas KM, Kosmehl H, Kaiser WA. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol 2004;14:1124-9.
23. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471-8.
24. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
25. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
26. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-18.
27. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006;94:247-52.
28. Corsten MF, Hofstra L, Narula J, Reutelingsperger CP. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 2006;66:1255-60.
29. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
30. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
31. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
32. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
33. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
34. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Chamsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;26:481-95.
35. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8.